The role of bronchoalveolar lavage in diffuse parenchymal lung diseases

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 5, 2005, Pages 417-421

  Kilinç, Günseli ^a   Kolsuk, Elif Altuǧ ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

Author keywords

Bronchoalveolar lavage; Diagnosis; Diffuse lung disease

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; RANTES; SURFACTANT PROTEIN A; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLERGIC PNEUMONITIS; CELL DIFFERENTIATION; DRUG INDUCED DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLITIS; LUNG DISEASE; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTE COUNT; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SYSTEMIC SCLEROSIS;

EID: 24744463354     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000175522.49353.e1     Document Type: Review

References (45)

1. American Thoracic Society. European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Med 2002; 165:277-304.
2. British Thoracic Society. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54(suppl 1):S1-S30.
3. Hansell DM. High-resolution computed tomography in the evaluation of fibrosing alveolitis. Clin Chest Med 1999; 20:739-760.
4. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
5. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 1999; 14:245-248.
6. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. Am Rev Respir Dis 1990; 141:S169-S202.
7. Costabel U, Guzman J. Effect of smoking on bronchoalveolar lavage constituents. Eur Respir J 1992; 5:776-779.
8. Fontenot AP, Schwarz MI. Diffuse alveolar hemorrhage. In: Schwarz MI, King Jr TE, editors. Interstitial lung disease. Hamilton (Ontario, Canada): BC Decker; 2003, p.632-56.
9. Martin RJ, Colason JJ, Rogers RM, et al. Pulmonary alveolar proteinosis: the diagnosis by segmental lavage. Am Rev Respir Dis 1980; 121:819-825.
10. Welker L, Jörres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung disease. Eur Respir J 2004; 24:1000-1006.
11. Costabel U. Atlas of bronchoalveolar lavage. London, Chapman and Hall, 1998.
12. Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 2001; 7:255-261.
13. Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-α by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 2005; 127:251-256.
14. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586.
15. Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic sclerosis. Curr Opin Pulm Med 2001; 7:283-290.
16. Meloni F, Caporali R, Marone Bianco A, et al. Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Ann Rheum Dis 2004; 63:892-894.
17. Clements PJ, Goldin JG, Kleerup EC, et al. Regional Differences in Bronchoalveolar Lavage and Thoracic High-Resolution Computed Tomography Results in Dyspneic Patients with systemic sclerosis. Arthritis Rheum 2004; 50:1909-1917.
18. Biederer J, Schanbel A, Muhle C, et al. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease asociated with rheumatoid arthritis. Eur Radiol 2004; 14:272-280.
19. Aghanouri R, Ghanei M, Aslani J, et al. Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1160-L1164.
20. Aubert JD, Dadal BI, Bai TR, et al. Transforming growth factor β1 gene expression in human airways. Thorax 1995; 49:225-232.
21. Khalil N, O'Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5:155-162.
22. Ziesche R, Hofbauer E, Witmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341:1264-1269.
23. Huang MS, Colby T, Goellner JR, et al. Utility of bronchoalveolar lavage in the diagnosis of drug-induced pulmonary toxicity. Acta Cytol 1989; 33:533-538.
24. Israel-Biet D, Venet A, Caubarrere I, et al. Bronchoalveolar lavage in amiodarone pneumonitis. Cellular abnormalities and their relevance to pathogenesis. Chest 1987; 91:214-221.
25. White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in belomycin lung toxicity. Thorax 1987; 42:551-552.
26. Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 24:25-35.
27. Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2004; 31:619-625.
28. Cameron LA, Taha RA, Tsicopoulos A, et al. Airway epithelium expresses interleukin-18. Eur Respir J 1999; 14:553-559.
29. Yoshioka S, Mukae H, Sugiyama K, et al. High-BAL concentrations of RANTES in nonspesific interstitial pneumonia compared with usual interstitial pneumonia. Respir Med 2004; 98:945-951.
30. Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspesific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2001; 22:239-244.
31. Lacasse Y, Selman M, Costabel U, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003; 168:952-958.
32. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997; 77:931-962.
33. Phelps DS. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr Pathol Mol Med 2001; 20:269-292.
34. Vazquez de Lara LG, Beceril C, Montano M, et al. Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase -1 expression. Am J Physiol Lung Cell Mol Physiol 2000; 279:L950-L957.
35. Frerking I, Gunther A, Seeger W. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 2001; 27:1699-1717.
36. Hamm H, Luhrs J, Guzman RJ, et al. Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest 1994; 106:1766-1770.
37. McCormack FX, King TE, Bucher BL, et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152:751-759.
38. Gunther A, Schmidt R, Nix F, et al. Surfactant abnormalities in idiopathic pulmnary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J 1999; 14:565-573.
39. Baughman RP, Sternberg RI, Hull W, et al. Decreased surfactant protein-A in patients with bacterial pneumonia. Am Rev Respir Dis 1993; 147:653-657.
40. Hoover RR, Floros J. SP-A 3′-UTR is involved in the glucocorticoid inhibition of human SP-A gene expression. Am J Physiol Lung Cell Mol Physiol 1999; 276:L917-L924.
41. Phelps DS, Umstead TM, Mejia M, et al. Increased Surfactant Protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 2004; 125:617-625.
42. Kuwano K, Kunitake R, Kawasaki M, et al. P21 Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154:477-483.
43. Maeyama T, Kuwano K, Kawasaki M, et al. Upregulation of Fas-signaling molecules in lung apithelial cells from patients in idiopathic pulmonary fibrosis. Eur Respir J 2001; 17:180-189.
44. Plataki M, Koutsopoulos AV, Darivianaki K, et al. Expression of apoptotic and antiapoptotic markers in epitjelial cells in idiopathic pulmonary fibrosis. Chest 2005; 127:266-274.
45. Meyer KC. The role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med 2004; 637-649.